1. Home
  2. MLYS vs AVDL Comparison

MLYS vs AVDL Comparison

Compare MLYS & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • AVDL
  • Stock Information
  • Founded
  • MLYS 2019
  • AVDL 2015
  • Country
  • MLYS United States
  • AVDL Ireland
  • Employees
  • MLYS N/A
  • AVDL N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • MLYS Health Care
  • AVDL Health Care
  • Exchange
  • MLYS Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • MLYS 1.0B
  • AVDL 861.4M
  • IPO Year
  • MLYS 2023
  • AVDL 1996
  • Fundamental
  • Price
  • MLYS $13.67
  • AVDL $11.08
  • Analyst Decision
  • MLYS Strong Buy
  • AVDL Strong Buy
  • Analyst Count
  • MLYS 4
  • AVDL 7
  • Target Price
  • MLYS $27.00
  • AVDL $18.71
  • AVG Volume (30 Days)
  • MLYS 692.8K
  • AVDL 1.0M
  • Earning Date
  • MLYS 08-12-2025
  • AVDL 08-07-2025
  • Dividend Yield
  • MLYS N/A
  • AVDL N/A
  • EPS Growth
  • MLYS N/A
  • AVDL N/A
  • EPS
  • MLYS N/A
  • AVDL N/A
  • Revenue
  • MLYS N/A
  • AVDL $194,450,000.00
  • Revenue This Year
  • MLYS N/A
  • AVDL $56.78
  • Revenue Next Year
  • MLYS N/A
  • AVDL $30.46
  • P/E Ratio
  • MLYS N/A
  • AVDL N/A
  • Revenue Growth
  • MLYS N/A
  • AVDL 252.64
  • 52 Week Low
  • MLYS $8.24
  • AVDL $6.38
  • 52 Week High
  • MLYS $18.38
  • AVDL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 45.18
  • AVDL 63.51
  • Support Level
  • MLYS $13.41
  • AVDL $10.53
  • Resistance Level
  • MLYS $15.15
  • AVDL $11.03
  • Average True Range (ATR)
  • MLYS 0.73
  • AVDL 0.45
  • MACD
  • MLYS 0.01
  • AVDL -0.02
  • Stochastic Oscillator
  • MLYS 25.36
  • AVDL 73.33

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: